Doxycycline hyclate controlled release - POLYPID
Alternative Names: D-PLEX; D-PLEX-100; Doxycycline/polymer-lipid encapsulation matrix; PLEX-doxycyclineLatest Information Update: 06 Aug 2026
At a glance
- Originator POLYPID
- Class Antibacterials; Collagenases; Skin disorder therapies; Tetracyclines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Surgical wound infections
Most Recent Events
- 29 Jul 2026 US FDA assigns PDUFA action date of 28/11/2026 for Doxycyline hyclate controlled release for Surgical wound infections (Prevention)
- 29 Jul 2026 US FDA accepts NDA for Doxycycline hyclate controlled release for Surgical wound infections (Prevention, Adjunctive treatment) and grants Priority Review
- 21 Jul 2026 PolyPid expects US FDA acceptance of NDA in Surgical wound infections in August 2026